The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Top-line results from this midstage study was the shot in the arm that Arena's shareholders needed.
A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Key Data Points
Primary metrics and data points about Arena Pharmaceuticals.| Current Price: | $24.46 |
| Prev Close: | $24.53 |
| Open: | $24.59 |
| Bid: | $24.50 |
| Ask: | $24.55 |
| Day's Range: | $24.39 - $24.67 |
| 52wk Range: | $11.30 - $27.86 |
| Volume: | 62,193 |
| Avg Vol | 605,374 |
| Market Cap: | $959M |
| P/E (ttm): | -2.84 |
| EPS (ttm): | ($8.65) |
| Div & Yield: | $0.00 (0.0%) |
Company Rating
What our community thinks about Arena Pharmaceuticals.
CAPS Rating
CAPS All Stars
Powered by 
CEO Rating
The single most important factor in a company's success is the team that's leading the company.Amit Munshi, CEO
100% Approve
Based on 5 Ratings
Business Summary
Industry, sector and description for Arena Pharmaceuticals.A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Drug Makers